Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Nihon Pharmaceutical Co., Ltd
Information provided by (Responsible Party):
Nihon Pharmaceutical Co., Ltd Identifier:
First received: April 26, 2013
Last updated: October 14, 2014
Last verified: October 2014

Patients diagnosed with anti-aquaporin 4 antibody positive Neuromyelitis Optica spectrum disorder were confirmed based on diagnostic criteria. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive steroid plus therapy (1g/day for five consecutive days). Subsequently, patients who not provided adequate effect of therapy to steroids plus therapy will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Patients evaluated Quantification of nerve and spinal cord impairment (QOSI) and the Expanded Disability Status Scale (EDSS)/ Functional Systems (FS) and anti-aquaporin 4 antibody et al.

As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by one year after the start of the study treatment.

Condition Intervention Phase
Neuromyelitis Optica Spectrum Disorder
Drug: NPB-01
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

Resource links provided by NLM:

Further study details as provided by Nihon Pharmaceutical Co., Ltd:

Primary Outcome Measures:
  • Change from Baseline Quantification of nerve and spinal cord impairment (QOSI) at 29 days [ Time Frame: 29 days ] [ Designated as safety issue: No ]
  • Change from Baseline Expanded Disability Status Scale (EDSS)/ Functional Systems (FS) at 29 days [ Time Frame: 29 days ] [ Designated as safety issue: No ]
  • Change from Baseline anti-aquaporin 4 antibody at 29 days [ Time Frame: 29 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 7
Study Start Date: May 2013
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NPB-01
Intravenous immunoglobulin
Drug: NPB-01
Other Name: Intravenous immunoglobulin


Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients who become positive for anti-aquaporin 4 antibody or have becomed.
  2. Patients who have developed myelitis.
  3. Patients who run beyond greater than 30 days at least from last time in relapse.
  4. Patients who new neurological symptom or worsening neurological symptom or flared neurological symptom have sustained 24 hours at least not associated fever or infection.
  5. Patients who have an acute exacerbation at informed consent.
  6. Patients who need steroid plus therapy(1g/day for five consecutive days).
  7. Patients who can start steroid plus therapy within 3 days after informed consent.
  8. Patients who be inadequate to effect to steroid plus therapy.
  9. Patients with greater than or equal to twenty years old at informed consent.

Exclusion Criteria:

  1. Patients who have developed optic neuritis.
  2. Patients treated with intravenous immunoglobulin within 14 days before informed consent.
  3. Patients with malignancy at informed consent.
  4. Patients with history of shock or hypersensitivity for NPB-01.
  5. Patients with IgA deficiency.
  6. Patients with impaired liver function.
  7. Patients with impaired renal function.
  8. Patients with cerebro- or cardiovascular disorders.
  9. Patients with high risk of thromboembolism.
  10. Patients with hemolytic/hemorrhagic anemia.
  11. Patients with decreased cardiac function.
  12. Patients with decreased platelet.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01845584

Japan Recruiting
Osaka,, Japan
Contact: Yasumasa Ogawa   
Sponsors and Collaborators
Nihon Pharmaceutical Co., Ltd
  More Information

No publications provided

Responsible Party: Nihon Pharmaceutical Co., Ltd Identifier: NCT01845584     History of Changes
Other Study ID Numbers: NPB-01-08/E-01
Study First Received: April 26, 2013
Last Updated: October 14, 2014
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Keywords provided by Nihon Pharmaceutical Co., Ltd:
IVIG in Neuromyelitis Optica spectrum disorder
Patients with Neuromyelitis Optica spectrum disorder

Additional relevant MeSH terms:
Neuromyelitis Optica
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Cranial Nerve Diseases
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Eye Diseases
Immune System Diseases
Multiple Sclerosis
Myelitis, Transverse
Nervous System Diseases
Optic Nerve Diseases
Optic Neuritis
Pathologic Processes
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs processed this record on February 27, 2015